SCHEMBL15470715

SCHEMBL15470715

CCOC(=O)Cc1nc2cc(C(=O)OC(C)(C)C)ccc2s1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 6/20 0.47
▸ RAB9A P51151 6/20 0.47
▸ SMN1; SMN2 Q16637 6/20 0.47
▸ PKM P14618 2/20 0.47
▸ NFKB1 P19838 1/20 0.47
▸ NFKB2 Q00653 1/20 0.47
▸ RELA Q04206 1/20 0.47
▸ L3MBTL1 Q9Y468 1/20 0.47
▸ MAPT P10636 3/20 0.46
▸ KDM4E B2RXH2 2/20 0.46
▸ GAA P10253 2/20 0.46
▸ MEN1 O00255 2/20 0.46
▸ KMT2A Q03164 2/20 0.46
▸ STAT1 P42224 1/20 0.42
▸ TRPV1 Q8NER1 7/20 0.42
▸ HDAC6 Q9UBN7 2/20 0.42
▸ ALDH1A1 P00352 2/20 0.40
▸ ALPL P05186 1/20 0.40
▸ HPGD P15428 1/20 0.40
▸ LIPG Q9Y5X9 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15427293 0.91 NPC1 (0.53) NPC1RAB9ASMN1; SMN2NFKB1NFKB2
SCHEMBL15464454 0.84 NPC1 (0.59) NPC1RAB9ASMN1; SMN2PKMNFKB1
SCHEMBL29462432 0.84 NPC1 (0.59) NPC1RAB9ASMN1; SMN2PKMNFKB1
SCHEMBL30016140 0.78 HDAC6 (0.56) NPC1RAB9ASMN1; SMN2PKMNFKB1
SCHEMBL489308 0.78 SMN1; SMN2 (0.52) NPC1RAB9ASMN1; SMN2PKMNFKB1
SCHEMBL13108323 0.78 HDAC6 (0.56) NPC1RAB9ASMN1; SMN2PKMNFKB1
SCHEMBL15470710 0.75 LIPG (0.51) TRPV1LIPG
SCHEMBL23500947 0.75 RAB9A (0.44) NPC1RAB9ASMN1; SMN2MAPTGAA
SCHEMBL29647831 0.75 MAPT (0.75) NPC1RAB9ASMN1; SMN2PKMNFKB1
SCHEMBL3100413 0.75 MAPT (0.75) NPC1RAB9ASMN1; SMN2PKMNFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2875007-B1 AMIDE, UREA OR SULFONE AMIDE LINKED BENZOTHIAZOLE INHIBITORS OF ENDOTHELIAL LIPASE BRISTOL MYERS SQUIBB CO (US) 2016-08-24 — — EP disclosed
US-8987314-B2 Amide, urea or sulfone amide linked benzothiazole inhibitors of endothelial lipase BRISTOL-MYERS SQUIBB COMPANY (US) 2015-03-24 — — US disclosed
US-20140045811-A1 AMIDE, UREA OR SULFONE AMIDE LINKED BENZOTHIAZOLE INHIBITORS OF ENDOTHELIAL LIPASE BRISTOL-MYERS SQUIBB COMPANY 2014-02-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140045811-A1 AMIDE, UREA OR SULFONE AMIDE LINKED BENZOTHIAZOLE INHIBITORS OF ENDOTHELIAL LIPASE LIPG, LIPE, CEL NPC1 1652/4885RAB9A 4013/4885SMN1; SMN2 4524/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback